{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:27:15Z","timestamp":1792099635510,"version":"4.4.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,4,10]],"date-time":"2018-04-10T00:00:00Z","timestamp":1523318400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI11-00842"],"award-info":[{"award-number":["PI11-00842"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shire Ib\u00e9rica Human Genetic Therapies"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13023-018-0792-8","type":"journal-article","created":{"date-parts":[[2018,4,19]],"date-time":"2018-04-19T11:12:55Z","timestamp":1524136375000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Fabry disease in the Spanish population: observational study with detection of 77 patients"],"prefix":"10.1186","volume":"13","author":[{"given":"Irene","family":"Vieitez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Souto-Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena","family":"Fernandez-Mosquera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"San Millan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Teijeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Fernandez-Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felisa","family":"Martinez-Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Jose","family":"Aldamiz-Echevarria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Lopez-Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1098-3376","authenticated-orcid":false,"given":"Saida","family":"Ortolano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,4,10]]},"reference":[{"key":"792_CR1","doi-asserted-by":"crossref","unstructured":"Mehta A, Hughes DA. Fabry disease. In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, et al. editors. Gene Reviews. Seattle: University of Washington; 1993-2017. [Updated 5 Jan 2017].","DOI":"10.1002\/9781118514672.ch7"},{"key":"792_CR2","doi-asserted-by":"crossref","unstructured":"Navarro C, Teijeira S, Ortolano S, Fernandez JM, San Millan B, Fachal C, et al. Histopathology of skin in Fabry disease. In: Elstein D, Altarescu G, Beck M, editors. Fabry disease: Springer; 2010. p. 275\u201392.","DOI":"10.1007\/978-90-481-9033-1_15"},{"issue":"2","key":"792_CR3","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1007\/s00401-005-0026-8","volume":"111","author":"C Navarro","year":"2006","unstructured":"Navarro C, Teijeira S, Dominguez C, Fernandez JM, Rivas E, Fachal C, et al. Fabry disease: an ultrastructural comparative study of skin in hemizygous and heterozygous patients. Acta Neuropathol. 2006;111(2):178\u201385.","journal-title":"Acta Neuropathol"},{"key":"792_CR4","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1016\/j.jacc.2007.06.062","volume":"25","author":"L Monserrat","year":"2007","unstructured":"Monserrat L, Gimeno-Blanes JR, Marin F, Hermida-Prieto F, Garcia-Honrubia A, Perez I, et al. Prevalence of FD in a cohort of 508 unrelated patients with hypertrophic cardiomyopathy. JACC. 2007;25:2399\u2013403.","journal-title":"JACC"},{"key":"792_CR5","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1046\/j.1523-1755.2003.00160.x","volume":"64","author":"S Nakao","year":"2003","unstructured":"Nakao S, Kodama C, Takenaka T, Tanaka A, Yasumoto Y, Yoshida A, et al. Fabry disease: detection of undiagnosed hemodialysis patients and identification of a \u201crenal variant\u201d phenotype. Kidney Int. 2003;64:801\u20137.","journal-title":"Kidney Int"},{"key":"792_CR6","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1038\/gim.2016.55","volume":"18","author":"R Schiffmann","year":"2016","unstructured":"Schiffmann R, Fuller M, Clarke LA, Aerts J. Is it Fabry disease? Genet Med. 2016;18:1181\u20135.","journal-title":"Genet Med"},{"key":"792_CR7","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1053\/j.semperi.2015.03.005","volume":"39","author":"D Matern","year":"2015","unstructured":"Matern D, Gavrilov D, Oglesbee D, Raymond K, Rinaldo P, Tortorelli S. Newborn screening for lysosomal storage disorders. Sem Perinatol. 2015;39:206\u201316.","journal-title":"Sem Perinatol"},{"key":"792_CR8","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1136\/bjo.2009.176651","volume":"94","author":"LE Allen","year":"2010","unstructured":"Allen LE, Cosgrave EM, Kersey JP, Ramaswami U. Fabry disease in children: correlation between ocular manifestations, genotype and systemic clinical severity. Br J Ophthalmol. 2010;94:1602\u20135.","journal-title":"Br J Ophthalmol"},{"key":"792_CR9","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1001\/jama.281.3.249","volume":"281","author":"PJ Meikle","year":"1999","unstructured":"Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. J Am Med Assoc. 1999;281:249\u201354.","journal-title":"J Am Med Assoc"},{"key":"792_CR10","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.jpeds.2013.01.031","volume":"163","author":"CR Scott","year":"2013","unstructured":"Scott CR, Elliott S, Buroker N, Thomas LI, Keutzer J, Glass M, et al. Identification of infants at risk for developing Fabry, Pompe, or mucopolysaccharidosis-I from newborn blood spots by tandem mass spectrometry. J Pediatr. 2013;163:498\u2013503.","journal-title":"J Pediatr"},{"key":"792_CR11","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.jpeds.2014.09.023","volume":"166","author":"PV Hopkins","year":"2015","unstructured":"Hopkins PV, Campbell C, Klug T, Rogers S, Raburn-Miller J, Kiesling J. Lysosomal storage disorder screening implementation: findings from the first six months of full population pilot testing in Missouri. J Pediatr. 2015;166:172\u20137.","journal-title":"J Pediatr"},{"key":"792_CR12","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1007\/s10157-015-1146-7","volume":"20","author":"O Saito","year":"2016","unstructured":"Saito O, Kusano E, Akimoto T, Asano Y, Kitagawa T, Suzuki K, et al. Prevalence of Fabry disease in dialysis patients: Japan Fabry disease screening study (J-FAST). Clin Exp Nephrol. 2016;20:284\u201393.","journal-title":"Clin Exp Nephrol"},{"key":"792_CR13","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ymgmr.2015.05.006","volume":"4","author":"G Serebrinsky","year":"2015","unstructured":"Serebrinsky G, Calvo M, Fernandez S, Saito S, Ohno K, Wallace E, et al. Late onset variants in Fabry disease: results in high risk population screenings in Argentina. Mol Genet Metab Rep. 2015;4:19\u201324.","journal-title":"Mol Genet Metab Rep"},{"key":"792_CR14","doi-asserted-by":"publisher","first-page":"3435","DOI":"10.2147\/DDDT.S80928","volume":"9","author":"L Golan","year":"2015","unstructured":"Golan L, Goker-Alpan O, Holida M, Kantola I, Klopotowski M, Kuusisto J, et al. Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy in adults with Fabry disease. J Drug Design Dev Ther. 2015;9:3435\u201344.","journal-title":"J Drug Design Dev Ther"},{"issue":"6","key":"792_CR15","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1510198","volume":"375","author":"DP Germain","year":"2016","unstructured":"Germain DP, Hughes DA, Nicholls K, Bichet DG, Giugliani R, Wilcox WR, et al. Treatment of Fabry's disease with the pharmacologic chaperone Migalastat. N Engl J Med. 2016;375(6):545\u201355.","journal-title":"N Engl J Med"},{"key":"792_CR16","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/S0009-8981(01)00478-8","volume":"308","author":"NA Chamoles","year":"2001","unstructured":"Chamoles NA, Blanco M, Gaggioli D. Fabry disease: enzymatic diagnosis in dried blood spots on filter paper. Clin Chim Acta. 2001;308:195\u20136.","journal-title":"Clin Chim Acta"},{"key":"792_CR17","first-page":"unit7.20","volume":"7","author":"I Adzhubei","year":"2013","unstructured":"Adzhubei I, Jordan DM, Sunyaev SR. Predicting functional effect of human missense mutations using PolyPhen-2. Curr Protoc Hum Genet. 2013;7:unit7.20.","journal-title":"Curr Protoc Hum Genet"},{"issue":"7","key":"792_CR18","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1038\/nprot.2009.86","volume":"4","author":"P Kumar","year":"2009","unstructured":"Kumar P, Henikoff S, Ng PC. Predicting the effects of coding nonsynonymous variants on protein function using the SIFT algorithm. Nat Protoc. 2009;4(7):1073\u201381.","journal-title":"Nat Protoc"},{"issue":"4","key":"792_CR19","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1002\/prot.20252","volume":"57","author":"C Ferrer-Costa","year":"2004","unstructured":"Ferrer-Costa C, Orozco M, de la Cruz X. Sequence-based prediction of pathological mutations. Proteins. 2004;57(4):811\u20139.","journal-title":"Proteins"},{"issue":"4","key":"792_CR20","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/nmeth.2890","volume":"11","author":"JM Schwarz","year":"2014","unstructured":"Schwarz JM, Cooper DN, Schuelke M, Seelow D. MutationTaster2: mutation prediction for the deep-sequencing age. Nat Methods. 2014;11(4):361\u20132.","journal-title":"Nat Methods"},{"key":"792_CR21","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1093\/nar\/29.9.e45","volume":"29","author":"MW Pfaffl","year":"2001","unstructured":"Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001;29:e45.","journal-title":"Nucleic Acids Res"},{"issue":"8","key":"792_CR22","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1111\/j.1742-1241.2011.02695.x","volume":"65","author":"MA Barba-Romero","year":"2011","unstructured":"Barba-Romero MA, Rivera-Gallego A, Pintos-Morell G. Fos study group. Fabry disease in Spain: description of Spanish patients and a comparison with other European countries using data from the Fabry outcome survey (FOS). Int J Clin Pract. 2011;65(8):903\u201310.","journal-title":"Int J Clin Pract"},{"issue":"3","key":"792_CR23","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.nefro.2015.12.003","volume":"36","author":"MA Azancot","year":"2016","unstructured":"Azancot MA, Vila J, Dominguez C, Serres X, Espinel E. Multiples quistes paraplenicos en la enfermedad de Fabry. Nefrologia. 2016;36(3):310\u20132.","journal-title":"Nefrologia"},{"issue":"Suppl 1","key":"792_CR24","first-page":"12","volume":"35","author":"E Corchete","year":"2015","unstructured":"Corchete E, Albalate R, Alcazar M, Ortega M, Puerta M, Desequera P, et al. \u00bfEs necesario una dosis individualizada en los pacientes con enfermedad de Fabry? [is it necessary to individualize the dose in patients with FD]. Nefrologia. 2015;35(Suppl 1):12.","journal-title":"Nefrologia"},{"issue":"1","key":"792_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/jmedgenet-2013-101857","volume":"51","author":"L Van der Tol","year":"2014","unstructured":"Van der Tol L, Smid BE, Poorthuis BJ, Biegstraaten M, Deprez RH, Linthorst GE, et al. A systematic review on screening for Fabry disease: prevalence of individuals with genetic variants of unknown significance. J Med Genet. 2014;51(1):1\u20139.","journal-title":"J Med Genet"},{"issue":"8","key":"792_CR26","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1007\/s00431-017-2950-8","volume":"176","author":"C Colon","year":"2017","unstructured":"Colon C, Ortolano S, Crespo M, Alvarez V, Lopez-Suarez OE, Couce ML, et al. Newborn screening for Fabry Disease in the Northwest of Spain. Eur J Pediatr. 2017;176(8):1075\u201381.","journal-title":"Eur J Pediatr"},{"issue":"2","key":"792_CR27","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s10545-010-9261-9","volume":"34","author":"A Gal","year":"2011","unstructured":"Gal A, Hughes DA, Winchester B. Towards a consensus in the diagnostics of Fabry disease recommendations of a European expert group. J Inherit Metab Dis. 2011;34(2):509\u201314.","journal-title":"J Inherit Metab Dis"},{"key":"792_CR28","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/1471-2261-12-39","volume":"12","author":"A Pisani","year":"2012","unstructured":"Pisani A, Imbriaco M, Zizzo C, et al. A classical phenotype of Anderson-Fabry disease in a female patient with intronic mutations of the GLA gene: a case report. BMC Cardiovasc Disord. 2012;12:39\u201342.","journal-title":"BMC Cardiovasc Disord"},{"key":"792_CR29","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.gene.2014.08.004","volume":"549","author":"DA Zeevi","year":"2014","unstructured":"Zeevi DA, Hakam-Spector E, Herskovitz Y, Beeri R, Elstein D, Altarescu G. An intronic haplotype in \u03b1-galactosidase a is associated with reduced mRNA expression in males with cryptogenic stroke. Gene. 2014;549:275\u20139.","journal-title":"Gene"},{"key":"792_CR30","doi-asserted-by":"publisher","unstructured":"Schelleckes M, Lenders M, Guske K, Schmitz B, Tanislav C, St\u00e4nder S, et al. Cryptogenic stroke and small fiber neuropathy of unknown etiology in patients with alpha-galactosidase a -10T genotype. OJRD. 2014; \n                    https:\/\/doi.org\/10.1186\/s13023-014-0178-5\n                    \n                  .","DOI":"10.1186\/s13023-014-0178-5"},{"key":"792_CR31","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/8904_2015_424","volume":"23","author":"S Ferreira","year":"2015","unstructured":"Ferreira S, Requenga C, Oliveira JP. The modulatory effects of the polymorphisms in GLA 5'-untranslated region upon gene expression are cell-type specific. JIMD Rep. 2015;23:27\u201334.","journal-title":"JIMD Rep"},{"key":"792_CR32","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s12863-015-0267-z","volume":"16","author":"J Gervas-Arruga","year":"2015","unstructured":"Gervas-Arruga J, Cebolla JJ, Irun P, Perez-Lopez J, Plaza L, Roche JC, et al. Increased glycolipid storage produced by the inheritance of a complex intronic haplotype in the alpha-galactosidase a gene (GLA). BMC Genomics. 2015;16:109\u201321.","journal-title":"BMC Genomics"},{"key":"792_CR33","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13023-016-0441-z","volume":"11","author":"M Lenders","year":"2016","unstructured":"Lenders M, Weidemann F, Kurschat C, Canaan-K\u00fchl S, Duning T, Stypmann J, et al. Alpha galactosidase a p.A143T, a non fabry disease causing variant. Orphanet J Rare Dis. 2016;11:54. \n                    https:\/\/doi.org\/10.1186\/s13023-016-0441-z\n                    \n                  .","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"792_CR34","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1681\/ASN.2016090964","volume":"28","author":"M Arends","year":"2017","unstructured":"Arends M, Wanner C, Hughes DA, Mehta A, Oder D, Watkinson OT, et al. Characterization of classical and non classical Fabry disease: a multicenter study. J Am Soc Nephrol. 2017;28(5):1631\u201341.","journal-title":"J Am Soc Nephrol"},{"key":"792_CR35","doi-asserted-by":"publisher","first-page":"e0161330","DOI":"10.1371\/journal.pone.0161330","volume":"11","author":"X Pan","year":"2016","unstructured":"Pan X, Ouyang Y, Wang Z, Ren H, Shen P, Wang W, et al. Genotype: a crucial but not unique factor affecting the clinical phenotypes in Fabry disease. PLoS One. 2016;11:e0161330.","journal-title":"PLoS One"},{"key":"792_CR36","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/humu.9172","volume":"22","author":"A Rodriguez-Mari","year":"2003","unstructured":"Rodriguez-Mari A, Coll MJ, Chabas A. Molecular analysis in Fabry disease in Spain: fifteen novel GLA mutations and identification of a homozygous female. Hum Mutat. 2003;22:25\u2013264.","journal-title":"Hum Mutat"},{"key":"792_CR37","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S1096-7192(02)00012-4","volume":"76","author":"J Shabbeer","year":"2002","unstructured":"Shabbeer J, Yasuda M, Luca E, Desnick RJ. Fabry disease: 45 novel mutations in the alpha-galactosidase a gene causing the classical phenotype. Mol Genet Metab. 2002;76:23\u201330.","journal-title":"Mol Genet Metab"},{"key":"792_CR38","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1093\/hmg\/2.7.1051","volume":"2","author":"JP Davies","year":"1993","unstructured":"Davies JP, Winchester BG, Malcom S. Mutation analysis in patients with the typical form of Anderson-Fabry disease. Hum Mol Genet. 1993;2:1051\u20133.","journal-title":"Hum Mol Genet"},{"key":"792_CR39","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1136\/jmg.40.4.e38","volume":"40","author":"N Guffon","year":"2003","unstructured":"Guffon N. Clinical presentation in female patients with Fabry disease. J Med Genet. 2003;40:e38\u20139.","journal-title":"J Med Genet"},{"key":"792_CR40","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s00109-005-0656-2","volume":"83","author":"R Dobrovolny","year":"2005","unstructured":"Dobrovolny R, Dvorakova L, Ledvinova J, Magage S, Bultas J, Lubanda JC, et al. Relationship between X-inactivation and clinical involvement in Fabry heterozygotes. Eleven novel mutations in the alpha-galactosidase a gene in the Czech and Slovak population. J Mol Med. 2005;83:647\u201354.","journal-title":"J Mol Med"},{"key":"792_CR41","first-page":"1186","volume":"53","author":"CM Eng","year":"1993","unstructured":"Eng CM, Resnick-Silverman LA, Niehaus DJ, Astrin KH, Desnick RJ. Nature and frequency of mutations in the alpha-galactosidase a gene that cause Fabry disease. Am J Hum Genet. 1993;53:1186\u201397.","journal-title":"Am J Hum Genet"},{"key":"792_CR42","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/BF03401671","volume":"3","author":"CM Eng","year":"1997","unstructured":"Eng CM, Ashley GA, Burgert TS, Enriquez AL, D'Souza M, Desnick RJ. Fabry disease: thirty-five mutations in the alpha-galactosidase a gene in patients with classic and variant phenotypes. Mol Med. 1997;3:174\u201382.","journal-title":"Mol Med"},{"key":"792_CR43","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1086\/376608","volume":"73","author":"M Yasuda","year":"2003","unstructured":"Yasuda M, Shabbeer J, Osawa M, Desnick RJ. Fabry disease: novel alpha-galactosidase a 3\u2032-terminal mutations result in multiple transcripts due to aberrant 3\u2032-end formation. Am J Hum Genet. 2003;73:162\u201373.","journal-title":"Am J Hum Genet"},{"key":"792_CR44","first-page":"489","volume":"22","author":"ZX Wang","year":"2005","unstructured":"Wang ZX, Zhang Y, Bu DF, Zhang W, Yuan Y. Novel GLA gene mutations in two Chinese families with classic Fabry disease. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2005;22:489\u201392.","journal-title":"Zhonghua Yi Xue Yi Chuan Xue Za Zhi"},{"key":"792_CR45","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1093\/hmg\/3.10.1795","volume":"3","author":"CM Eng","year":"1994","unstructured":"Eng CM, Dj N, Enriquez AL, Burgert TS, Ludman MD, Desnick RJ. Fabry disease: twenty-three mutations including sense and antisense CpG alterations and identification of a deletional hot-spot in the alpha-galactosidase a gene. Hum Mol Genet. 1994;3:1795\u20139.","journal-title":"Hum Mol Genet"},{"key":"792_CR46","first-page":"535","volume":"107","author":"A Cooper","year":"2000","unstructured":"Cooper A, Cooper JA, Wraith JE. Human gene mutations in GLA. Hum Genet. 2000;107:535\u20136.","journal-title":"Hum Genet"},{"key":"792_CR47","unstructured":"https:\/\/www.ncbi.nlm.nih.gov\/clinvar\/RCV000207780\/\n                    \n                  . Accessed Apr 5 2018."},{"issue":"6","key":"792_CR48","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/jhg.2012.32","volume":"57","author":"LT Tura\u00e7a","year":"2012","unstructured":"Tura\u00e7a LT, Pessoa JG, Motta FL, Mu\u00f1oz Rojas MV, Barbosa-M\u00fcller K, Marques-Louren\u00e7o C, et al. New mutations in the GLA gene in Brazilian families with Fabry disease. J Hum Genet. 2012;57(6):347\u201351.","journal-title":"J Hum Genet"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-018-0792-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13023-018-0792-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-018-0792-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,9]],"date-time":"2019-04-09T19:51:41Z","timestamp":1554839501000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-018-0792-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,10]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["792"],"URL":"https:\/\/doi.org\/10.1186\/s13023-018-0792-8","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,10]]},"assertion":[{"value":"8 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Galician Clinical Research Ethics Committee (Ref 2009\/182, up-date on March 29th 2011). All patients involved in the study signed the informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SO, CN were principal investigators in projects sponsored by the pharmaceutical company Shire Ib\u00e9rica Human Genetic Therapies. SO, CN, BS, JFM, LJAE, MLR and FMS, have also been invited to attend or give conferences by Shire Ib\u00e9rica Human Genetic Therapies and or Sanofi-Genzyme.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"52"}}